The Life Sciences team advised CathWorks on its acquisition by Medtronic plc (NYSE:MDT), a global leader in healthcare technology, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the US, Europe, and Japan. The acquisition is valued at $585 million with potential undisclosed earn-out payments post-acquisition. This agreement continues Medtronic’s momentum in executing on strategic deals that strengthen the company’s leadership within its core franchises.
CathWorks, founded in Kfar Saba, Israel, is the leader in coronary digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFR values for the entire coronary tree.
The Goodwin team was led by Yasin Akbari and included Chris Denn, Matt Wetzel, Julie Tibbets, Steve Tjoe, Heath Ingram, Dan Karelitz, Benjamin Gossels, Karl Dragosz, Malhar Naik, Rich Matheny, Chris Steinroeder, and Paul Jin.
For more information on the deal, please read the press release.